COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide Tuesday, March 30, 2021

DISCLAIMER: These Alllandscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these
landscape documents Phasedoes1not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the
information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes),
Phasemerchantability
quality, safety, efficacy, 1/2 and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death,
Phase 2loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.
disability, injury, suffering,
Phase 2/3
Phase 3
Phase 4
Summary Information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical develop 84

184 84

2. - Number of vaccines in pre-clinical deve 184 Vaccines in clinical development 84

0 50 100 150 200 250 300
Vaccines in pre-clinical development 184
Vaccines in pre-clinical development Vaccines in clinical development

3. - Candidates in clinical phase 0% 5% 10% 15% 20% 25% 30% 35%

PS
Filter All Select phase of development (default is all) Chart Title
VVnr
Platform Candidate vaccines (no. and %) DNA
PS Protein subunit 27 32%
IV
VVnr Viral Vector (non-replicating) 12 14%
DNA DNA 10 12% RNA
IV Inactivated Virus 11 13% VVr
RNA RNA 11 13% VLP
VVr Viral Vector (replicating) 4 5%
VVr + APC
VLP Virus Like Particle 4 5%
VVr + APC VVr + Antigen Presenting Cell 2 2% LAV
LAV Live Attenuated Virus 2 2% VVnr + APC
VVnr + APC VVnr + Antigen Presenting Cell 1 1%
84

4. - Number of doses, schedule and route of administration of candidates in clinical phase

other not speci-
Number of doses & schedule Candidate vaccines (no. and %) fied Day 0
1 dose 13 15% 123%
dose 13 15%
Day 0 13 2 doses 51
2 doses 51 61% 3 doses 1
Day 0 + 14 6 other not 19
Day 0 + 21 19
1 dose
Day 0 + 28 26 Day 0 13 Day 0 + 14
3 doses 1 1% Day 0 + 6 7%
Day 0 + 28 + 56 1 Day 0 + 19
Day 0 + 28 + 56 3 doses
TBD / No Data (ND) 19 23% Day 0 + 26
1%
84 Day 0 + 1
Route of administration other not 19
Oral 2 2%
Injectable 69 82%
2 doses
SC Sub cutaneous 3 4%
ID Intra dermal 3 4%
Day 0 + 21
IM Intra muscular 63 75%
23%
TBD / No Data (ND) 13 15% Day 0 + 28
31%
Landscape of candidate vaccines in clinical development Tuesday, March 30, 2021
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these
landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information
presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety,
efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury,
suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week is highlighted in yellow
(NCT04510207 *) This Phase 3 trial assesses both the Wuhan and Beijing vaccine in the same study.
**Pending confirmation on the phase of study which is not specified in the registry.
The informaion provided is taken directly from data available in the trial registries. In cases where the trial is registrered as N/A or without a
defined clincial phase, it has been listed in the column "Phase not reported".

Information highlighted in red indicates a change in the development of the vaccine Current status of clinical evaluation

Vaccine Number of Route of

ID platform Vaccine platform description Type of candidate vaccine doses Schedule administration Developers Phase Phase 1 Phase 1/2
acronym

1 IV Inactivated virus CoronaVac; SARS-CoV-2 vaccine (inactivated) 2 Day 0 + 14 IM Sinovac Research and Development Co., Ltd Phase 4 NCT04383574
Study Report
NCT04352608
NCT04551547
Study Report
Study Report

Sinopharm + China National Biotec Group Co + Wuhan Institute

2 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 2 Day 0 + 21 IM Phase 3 ChiCTR2000031809
of Biological Products

Interim Report
Inactivated SARS-CoV-2 vaccine (Vero cell), vaccine name BBIBP- Sinopharm + China National Biotec Group Co + Beijing Institute
3 IV Inactivated virus 2 Day 0 + 21 IM Phase 4 ChiCTR2000032459
CorV of Biological Products

Study Report
4 VVnr Viral vector (Non-replicating) ChAdOx1-S - (AZD1222) (Covishield) 1-2 Day 0 + 28 IM AstraZeneca + University of Oxford Phase 4 PACTR202005681895696 PACTR202006922165132
2020-001072-15
Interim Report
NCT04568031
Study Report
NCT04444674
NCT04324606
Study Report
Study Report
Study Report
NCT04684446
ISRCTN15638344
NCT04760730

5 VVnr Viral vector (Non-replicating) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) 1 Day 0 IM CanSino Biological Inc./Beijing Institute of Biotechnology Phase 3 ChiCTR2000030906

NCT04313127 NCT04398147
NCT04568811
NCT04552366
Study Report
6 VVnr Viral vector (Non-replicating) Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) 2 Day 0 + 21 IM Gamaleya Research Institute ; Health Ministry of the Russian Phase 3 NCT04436471
Federation

NCT04437875
NCT04713488
Study Report
NCT04760730

7 VVnr Viral vector (Non-replicating) Ad26.COV2.S 1-2 Day 0 or Day 0 +56 IM Janssen Pharmaceutical Phase 3 NCT04509947 NCT04436276

Study Report
Study Report
Study Report
8 PS Protein subunit SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS 2 Day 0 + 21 IM Novavax Phase 3
CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) NCT04368988
 Study Report
Study Report
9 RNA RNA based vaccine mRNA -1273 2 Day 0 + 28 IM Moderna + National Institute of Allergy and Infectious Diseases Phase 4
NCT04283461 NCT04677660
(NIAID)
Interim Report NCT04712110

Study Report

10 RNA RNA based vaccine BNT162 (3 LNP-mRNAs ), also known as "Comirnaty" 2 Day 0 + 21 IM Pfizer/BioNTech + Fosun Pharma Phase 4 NCT04523571 2020-001038-36
Study Report NCT04588480
ChiCTR2000034825 NCT04380701
Study Report
NCT04537949
EUCTR2020-003267-26-DE
Study Report
11 PS Protein subunit Recombinant SARS-CoV-2 vaccine (CHO Cell) 2-3 Day 0 + 28 or Day 0 IM Anhui Zhifei Longcom Biopharmaceutical + Institute of Phase 3
+ 28 + 56 Microbiology, Chinese Academy of Sciences NCT04445194 NCT04550351

ChiCTR2000035691
NCT04636333 NCT04813562
12 RNA RNA based vaccine CVnCoV Vaccine 2 Day 0 + 28 IM CureVac AG Phase 3 NCT04449276

13 IV Inactivated virus SARS-CoV-2 vaccine (vero cells) 2 Day 0 + 28 IM Institute of Medical Biology + Chinese Academy of Medical Phase 3 NCT04470609
Sciences

NCT04412538

Study Report

Research Institute for Biological Safety Problems, Rep of

14 IV Inactivated virus QazCovid-in® - COVID-19 inactivated vaccine 2 Day 0 + 21 IM Phase 3 NCT04530357
Kazakhstan
Inovio Pharmaceuticals + International Vaccine Institute +
15 DNA DNA based vaccine INO-4800+electroporation 2 Day 0 + 28 ID Phase 2/3 NCT04336410 NCT04447781
Advaccine (Suzhou) Biopharmaceutical Co., Ltd
Study Report
ChiCTR2000038152
16 DNA DNA based vaccine AG0301-COVID19 2 Day 0 + 14 IM AnGes + Takara Bio + Osaka University Phase 2/3 NCT04463472
NCT04527081
jRCT2051200085
17 DNA DNA based vaccine nCov vaccine 3 Day 0 + 28 + 56 ID Zydus Cadila Phase 3 CTRI/2020/07/026352
CTRI/2021/03/032051
18 DNA DNA based vaccine GX-19 2 Day 0 + 28 IM Genexine Consortium Phase 1/2 NCT04445389
NCT04715997
19 IV Inactivated virus Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) 2 Day 0 + 14 IM Bharat Biotech International Limited Phase 3
NCT04471519

Interim Study Report

Study Report
Study Report
Study report
CTRI/2020/07/026300
CTRI/2020/09/027674
20 PS Protein subunit KBP-COVID-19 (RBD-based) 2 Day 0 + 21 IM Kentucky Bioprocessing Inc. Phase 1/2 NCT04473690
21 PS Protein subunit VAT00002: SARS-CoV-2 S protein with adjuvant 2 Day 0 + 21 IM Sanofi Pasteur + GSK Phase 3 NCT04537208

22 RNA RNA based vaccine ARCT-021 ND ND IM Arcturus Therapeutics Phase 2 NCT04480957

23 VLP Virus like particle RBD SARS-CoV-2 HBsAg VLP vaccine 2 Day 0 + 28 IM Serum Institute of India + Accelagen Pty + SpyBiotech Phase 1/2 ACTRN12620000817943
ACTRN12620001308987
24 IV Inactivated virus Inactivated SARS-CoV-2 vaccine (Vero cell) 1,2 or 3 ND IM Beijing Minhai Biotechnology Co Phase 2 NCT04758273
GRAd-COV2 (Replication defective Simian Adenovirus (GRAd)
25 VVnr Viral vector (Non-replicating) 1 Day 0 IM ReiThera + Leukocare + Univercells Phase 2/3 NCT04528641
encoding S)

26 VVnr Viral vector (Non-replicating) VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform 2 Day 0 + 28 Oral Vaxart Phase 1 NCT04563702

27 VVnr Viral vector (Non-replicating) MVA-SARS-2-S 2 Day 0 + 28 IM University of Munich (Ludwig-Maximilians) Phase 1 NCT04569383
28 PS Protein subunit SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native 2 Day 0 + 21 IM Clover Biopharmaceuticals Inc./GSK/Dynavax Phase 2/3 NCT04405908
like Trimeric subunit Spike Protein vaccine)
Study Report
Report
29 PS Protein subunit COVAX-19® Recombinant spike protein + adjuvant 1 Day 0 IM Vaxine Pty Ltd. Phase 1 NCT04453852
Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 2 Day 0 + 28 IM CSL Ltd. + Seqirus + University of Queensland Phase 1 Development has been suspended and the candidate vaccine
30 PS Protein subunit MVC-COV1901 (S-2P protein + CpG 1018) 2 Day 0 + 28 IM Medigen Vaccine Biologics + Dynavax + National Institute of Phase 2 NCT04487210
Allergy and Infectious Diseases (NIAID)
31 PS Protein subunit FINLAY-FR1 anti-SARS-CoV-2 Vaccine (RBD + adjuvant) 2 Day 0 + 28 IM Instituto Finlay de Vacunas Phase 1/2 RPCEC00000338 RPCEC00000332

32 PS Protein subunit FINLAY-FR-2 anti-SARS-CoV-2 Vaccine (RBD chemically conjugated 2 Day 0 + 28 IM Instituto Finlay de Vacunas Phase 3 RPCEC00000340
to tetanus toxoid plus adjuvant)
33 PS Protein subunit EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for 2 Day 0 + 21 IM Federal Budgetary Research Institution State Research Center Phase 3 NCT04527575
the prevention of COVID-19) of Virology and Biotechnology "Vector"

34 PS Protein subunit RBD (baculovirus production expressed in Sf9 cells) Recombinant 2 Day 0 + 28 IM West China Hospital + Sichuan University Phase 2 ChiCTR2000037518
SARS-CoV-2 vaccine (Sf9 Cell)

NCT04530656

35 PS Protein subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) 1 Day 0 SC University Hospital Tuebingen Phase 1 NCT04546841

36 PS Protein subunit UB-612 (Multitope peptide based S1-RBD-protein based vaccine) 2 Day 0 + 28 IM COVAXX + United Biomedical Inc Phase 2/3 NCT04545749
Viral vector (Replicating) V591-001 - Measles-vector based (TMV-o38) 1-2 Day 0 + 28 IM Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + Phase 1/2 NCT04497298 CT04498247
University of Pittsburgh
NCT04569786
University of Hong Kong, Xiamen University and Beijing Wantai
37 VVr Viral vector (Replicating) DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) 1 Day 0 IN Phase 2 ChiCTR2000037782
Biological Pharmacy
38 RNA RNA based vaccine LNP-nCoVsaRNA 2 ND IM Imperial College London Phase 1 ISRCTN17072692
39 RNA RNA based vaccine SARS-CoV-2 mRNA vaccine (ARCoV) 2 Day 0 + 14 or IM Academy of Military Science (AMS), Walvax Biotechnology and Phase 2 ChiCTR2000034112
Day 0 + 28 Suzhou Abogen Biosciences
ChiCTR2000039212
40 VLP Virus like particle Coronavirus-Like Particle COVID-19 (CoVLP) 2 Day 0 + 21 IM Medicago Inc. Phase 2/3
Study Report

Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by

applying lentivirus modification with immune modulatory genes
41 VVr + APC Viral vector (Replicating) + APC 3 Day 0 + 14 + 28 SC Shenzhen Geno-Immune Medical Institute Phase 1 NCT04299724
and the viral minigenes to the artificial antigen presenting cells
(aAPCs).

LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus

Viral vector (Non-replicating) + vectors expressing Covid-19 minigene SMENP and immune
42 VVnr + APC 1 Day 0 SC & IV Shenzhen Geno-Immune Medical Institute Phase 1/2 NCT04276896
APC modulatory genes. CTLs are activated by LV-DC presenting Covid-19
specific antigens.

43 PS Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) ND ND ND Adimmune Corporation Phase 1 NCT04522089
Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV)
44 DNA DNA based vaccine 2 Day 0 + 14 IM Entos Pharmaceuticals Inc. Phase 1 NCT04591184
formulation
45 DNA DNA based vaccine CORVax - Spike (S) Protein Plasmid DNA Vaccine 2 Day 0 + 14 ID Providence Health & Services Phase 1 NCT04627675
46 RNA RNA based vaccine ChulaCov19 mRNA vaccine 2 Day 0 + 21 IM Chulalongkorn University Phase 1 NCT04566276
47 DNA DNA based vaccine bacTRL-Spike oral DNA vaccine 1 Day 0 Oral Symvivo Corporation Phase 1 NCT04334980

NCT04591717
Human Adenovirus Type 5: hAd5 S+N vaccine (S-Fusion + N-ETSD).
48 VVnr Viral vector (Non-replicating) 1-2 Day 0 + 21 SC or Oral ImmunityBio, Inc Phase 1
E2b- Deleted Adeno. NCT04710303
NCT04732468
COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA)
49 VVnr Viral vector (Non-replicating) 1-2 Day 0 + 28 IM City of Hope Medical Center + National Cancer Institute Phase 1 NCT04639466
platform + synthetic SARS-CoV-2
Pre-clinical result
50 VVr Viral vector (Replicating) rVSV-SARS-CoV-2-S Vaccine 1 Day 0 IM Israel Institute for Biological Research Phase 1/2 NCT04608305
51 VVr + APC Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19. A vaccine consisting of 1 Day 0 IM Aivita Biomedical, Inc. Phase 1/2 NCT04690387 NCT04386252
autologous dendritic cells loaded with antigens from SARS-CoV-2, National Institute of Health Research and Development,
with or without GM-CSF Ministry of Health Republic of Indonesia

NCT04685603
Day 0 or
52 LAV Live attenuated virus COVI-VAC 1-2 IN Codagenix/Serum Institute of India Phase 1 NCT04619628
Day 0 + 28
Day 0 + 14 + 28 or
53 PS Protein subunit CIGB-669 (RBD+AgnHB) 3 IN Center for Genetic Engineering and Biotechnology (CIGB) Phase 1/2 RPCEC00000345
Day 0 +28 + 56
Day 0 + 14 + 28 or
54 PS Protein subunit CIGB-66 (RBD+aluminium hydroxide) 3 IM Center for Genetic Engineering and Biotechnology (CIGB) Phase 3 RPCEC00000346
Day 0 +28 + 56
Valneva, National Institute for Health Research, United
55 IV Inactivated Virus VLA2001 2 Day 0 + 21 IM Phase 1/2 NCT04671017
Kingdom
56 PS Protein subunit BECOV2 2 Day 0 + 28 IM Biological E. Limited Phase 1/2 CTRI/2020/11/029032
57 VVr Viral vector (Replicating) AdCLD-CoV19 (adenovirus vector) 1 Day 0 IM Cellid Co., Ltd. Phase 1/2 NCT04666012
Day 0 + 56 or
58 DNA DNA based vaccine GLS-5310 2 ID GeneOne Life Science, Inc. Phase 1/2 NCT04673149
Day 0 + 84

59 PS Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted 2 Day 0 + 21 IM Nanogen Pharmaceutical Biotechnology Phase 1/2 NCT04683484

Recombinant protein vaccine S-268019 (using Baculovirus

60 PS Protein subunit 2 Day 0 + 21 IM Shionogi Phase 1/2 jRCT2051200092
expression vector system)

AdCOVID, Adenovirus-based platform expresses the receptor-

61 VVnr Viral vector (Non-replicating) 1-2 Day 0 IN Altimmune, Inc. Phase 1 NCT04679909
binding domain (RBD) of the Sars-Cov-2 spike protein
62 PS Protein subunit SARS-CoV-2-RBD-Fc fusion protein SC or IM University Medical Center Groningen + Akston Biosciences Inc. Phase 1/2 NCT04681092

63 IV Inactivated Virus ERUCOV-VAC, inactivated virus 2 Day 0 + 21 IM Erciyes University Phase 1 NCT04691947
COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE NCT04702178
64 PS Protein subunit 2 Day 0 + 28 IM University of Saskatchewan Phase 1/2
adjuvant
65 PS Protein subunit GBP510, a recombinant surface protein vaccine with adjuvant AS03 2 Day 0 + 28 IM SK Bioscience Co., Ltd. and CEPI Phase 1/2 NCT04742738
(aluminium hydroxide)
NCT04750343
66 PS Protein subunit Razi Cov Pars, recombinant spike protein 3 Day 0 + 21 +51 IM and IN Razi Vaccine and Serum Research Institute Phase 1 IRCT20201214049709N1
67 IV Inactivated Virus COVID-19 inactivated vaccine 2 Day 0 + 14 IM Shifa Pharmed Industrial Co Phase 1 IRCT20201202049567N1
IRCT20201202049567N2
68 PS Protein subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 2 Day 0 + 28 IM The University of Queensland Phase 1 NCT04495933
Study Report
University of Sydney, Bionet Co., Ltd
69 DNA DNA based vaccine COVIGEN 2 Day 0 + 28 ID or IM Phase 1 NCT04742842
Technovalia

70 DNA DNA based vaccine COVID-eVax, a candidate plasmid DNA vaccine of the Spike protein IM or Takis + Rottapharm Biotech Phase 1/2 NCT04788459

IM + electroporation EUCTR2020-003734-20-IT
71 VVnr Viral vector (Non-replicating) BBV154, Adenoviral vector COVID-19 vaccine 1 Day 0 IN Bharat Biotech International Limited Phase 1 NCT04751682
72 RNA RNA based vaccine PTX-COVID19-B, mRNA vaccine 2 Day 0 + 28 IM Providence Therapeutics Phase 1 NCT04765436
NDV-HXP-S, Newcastle disease virus (NDV) vector expressing the
Mahidol University; The Government Pharmaceutical
73 VVr Viral vector (Replicating) spike protein of SARS-CoV-2, with or without the adjuvant CpG 2 Day 0 + 28 IM Phase 1/2 NCT04764422
Organization (GPO); Icahn School of Medicine at Mount Sinai
1018

CoV2 SAM (LNP) vaccine. A self-amplifying mRNA (SAM) lipid

74 RNA RNA based vaccine Day 0 + 28 IM GlaxoSmithKline Phase 1 NCT04758962
nanoparticle (LNP) platform + Spike antigen

VBI-2902a. An enveloped virus-like particle (eVLP) of SARS-CoV-2

75 VLP Virus like particle 2 Day 0 + 28 IM VBI Vaccines Inc. Phase 1/2 NCT04773665
spike (S) glycoprotein and aluminum phosphate adjuvant.

SK SARS-CoV-2 recombinant surface antigen protein subunit

76 PS Protein subunit 2 Day 0 + 28 IM SK Bioscience Co., Ltd. Phase 1 NCT04760743
(NBP2001) + adjuvanted with alum.
VVnr Viral vector (Non-replicating) Chimpanzee Adenovirus serotype 68 (ChAd) and self-amplifying Day 0 + 14 + 28 or Gritstone Oncology
77 mRNA (SAM) vectors expressing spike alone, or spike plus 2-3 Day 0 +28 + 56 or IM Phase 1 NCT04776317
additional SARS-CoV-2 T cell epitopes. Day 0 + 112

RNA RNA based vaccine 3 Day 0 or Day 0 + 28 IM Moderna + National Institute of Allergy and Infectious Diseases Phase 1 NCT04785144
mRNA-1273.351. A lipid nanoparticle (LNP)-encapsulated mRNA- or Day 56 (NIAID)
78 based vaccine that encodes for a full-length, prefusion stabilized S
protein of the SARS-CoV-2 B.1.351 variant.

79 PS Protein subunit SpFN (spike ferritin nanoparticle) uses spike proteins with a Day 0 + 28 + 180 IM Walter Reed Army Institute of Research (WRAIR) Phase 1 NCT04784767
2-3
liposomal formulation QS21 (ALFQ) adjuvant.
80 PS Protein subunit EuCorVac-19; A spike protein using the recombinant protein 2 Day 0 + 21 IM POP Biotechnologies and EuBiologics Co.,Ltd Phase 1/2 NCT04783311
technology and with an adjuvant.
81 IV Inactivated virus Inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) 2 Day 0 + 14 +/- 21 IM Organization of Defensive Innovation and Research Phase 1 IRCT20210206050259N1

82 LAV Live attenuated virus MV-014-212, a live attenuated vaccine that expresses the spike (S) 3 Day 0 +/- 35 IN Meissa Vaccines, Inc. Phase 1 NCT04798001
protein of SARS-CoV-2
83 RNA RNA based vaccine MRT5500, an mRNA vaccine candidate 2 Day 0 + 21 IM Sanofi Pasteur and Translate Bio Phase 1/2 NCT04798027
84 VLP Virus like particle SARS-CoV-2 VLP Vaccine 2 Day 0 SC The Scientific and Technological Research Council of Turkey Phase 1 NCT04818281
Current status of clinical evaluation (Trial registries and public reports) Phase 3 endpoints as per protocol

Number of virologically Efficacy compared to placebo Efficacy against severe and Efficacy for the prevention of Efficacy of vaccine against Efficacy of vaccine against
confirmed (PCR or NAAT
Phase 2 Phase 2/3 Phase 3 Phase 4 Phase not reported positive) symptomatic cases of
for the prevention of SARS- non-severe COVID-19: hospital COVID-19-related Emergency severe and non-severe COVID- severe and non-severe COVID- Efficacy: seroconversion rates
CoV-2 infection admissions Department visits 19 19: number of deaths
COVID-19

NCT04456595 NCT04756830
X X X X
Study Protocol NCT04747821
NCT04508075 NCT04775069 X X X X X
NCT04582344 NCT04789356 X X X X X X
NCT04617483 NCT04754698 X
NCT04651790 NCT04801888 X X X X X X
NCT04800133
ChiCTR2000034780 X X X

ChiCTR2000039000 X X X X X
NCT04510207 * X X
NCT04612972 X X X X X

NCT04560881 ChiCTR2100041704 X X X X

ChiCTR2100041705

NCT04510207* ChiCTR2100041706 X X X X X
NCT04686773 NCT04400838 ISRCTN89951424 NCT04760132 NCT04794946 X X X X
Study Report NCT04516746 NCT04775069 X X X X
ISRCTN69254139 Study Report NCT04540393 X
Study Report NCT04536051 X X X X X
Study Report EUCTR2020-005226-28-DE X X X X X
Study Report
CTRI/2020/08/027170 Study Report
ISRCTN69254139 NCT04800133

ChiCTR2000031781 NCT04526990 X X X X

NCT04566770 NCT04540419 X X X X X X
NCT04341389

Study Report
NCT04530396 X X X

Study Report

NCT04564716 X X X
NCT04587219 NCT04642339 X X X
NCT04640233 NCT04656613 X X
NCT04741061 X X

EUCTR2020-002584-63-DE NCT04505722 X X X X X

NCT04535453 Study Report

NCT04765384 NCT04614948 X X X X

NCT04533399 NCT04611802 X X X X
 EUCTR2020-004123-16-GB X X X X
NCT04583995 X X X X X

NCT04405076 NCT04649151 NCT04470427 NCT04760132 X X X X

Study Report NCT04796896 Study Report NCT04792567

NCT04811664
NCT04761822 NCT04805125 X X X X X X
NCT04806113 X
NCT04649021 NCT04754594 NCT04368728 NCT04760132 X X X X
NCT04761822 Study Report EUCTR2021-000412-28-BE
Study Report EUCTR2021-000412-28-BE
NCT04713553 NCT04780659
NCT04800133 NCT04775069
NCT04805125 X X X X

NCT04466085

Study Report NCT04646590 X X X X

NCT04515147 NCT04652102 NCT04674189 X X X X

PER-054-20

NCT04659239 X X X

NCT04691908 X X X

ChiCTR2000040146 NCT04642638 X X X X X

NCT04655625 X X X

CTRI/2020/07/026352 X X X

X X X X
NCT04641481; CTRI/2020/11/028976

NCT04762680 PACTR202011523101903**

NCT04668339
NCT04728347

NCT04756323

NCT04791423

NCT04672395 X X X X

Development has been suspended and the candidate vaccine has been removed from the landscape summary analysis
NCT04695652

RPCEC00000347 RPCEC00000354
 NCT04780035

ChiCTR2000039994

NCT04640402

NCT04718467

NCT04773067 NCT04683224 X X X X

Development has been suspended and the candidate vaccines has been removed from the landscape summary analysis

ChiCTR2000039715

ChiCTR2100041855

NCT04662697 NCT04636697 X X X X

RPCEC00000359
IRCT20201202049567N3
 Assess humoral
immunogenicity : antibody Safety and immunogenicity of
quantification a booster dose

X X

X X
X X
X X
X X

X X

X X
X X
X

X X

X X
X X
X X
X X
X
X X

X X

X X
X X
X X
X X

X X

X X

X X
 X
X

X X

X X
X X
X X

X X

X X

X X

X X

X X

X X

X X

X X

X X

X X

X X
X X

X X
Landscape of candidate vaccines in pre-clinical development
DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents
does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape
documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-
infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind
that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

New information that has been added this week.

Vaccine Same platform for non-

ID platform Vaccine platform description Type of candidate vaccine Coronavirus target Coronavirus candidates
acronym

1 DNA DNA based vaccine DNA, engineered vaccine inserts compatible with multiple delivery systems SARS-CoV-2 and Sarbeco-
CoV
2 DNA DNA based vaccine DNA vaccine SARS-CoV2
3 DNA DNA based vaccine DNA plasmid vaccine RBD&N SARS-CoV2
4 DNA DNA based vaccine DNA with electroporation SARS-CoV2
5 DNA DNA based vaccine DNA with electroporation SARS-CoV2
6 DNA DNA based vaccine Plasmid DNA, Needle-Free Delivery SARS-CoV2 SARS
7 DNA DNA based vaccine DNA plasmid vaccine S,S1,S2,RBD &N SARS-CoV2
8 DNA DNA based vaccine DNA vaccine SARS-CoV2
9 DNA DNA based vaccine msDNA vaccine SARS-CoV2
10 DNA DNA based vaccine DNA vaccine SARS-CoV2
11 DNA DNA based vaccine DNA plasmids containing S-gene SARS-CoV2
12 DNA DNA based vaccine DNA plasmid vaccine SARS-CoV2
13 DNA DNA based vaccine Plasmid DNA, nanostructured RBD SARS-CoV2
14 DNA DNA based vaccine DNA plasmid vaccine encoding RBD SARS-CoV2
15 DNA DNA based vaccine DNA Immunostimulatory sequences SARS-CoV2
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)
16 IV Viral vector (Non-replicating) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV2
protein (Hexapro) + CpG 1018

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)

17 18 Inactivated virus expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV2
protein (Hexapro) + CpG 1018

Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV)

18 IV Inactivated virus expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S SARS-CoV-2
protein (Hexapro) + CpG 1018
19 IV Inactivated virus Inactivated + alum SARS-CoV2 JE, Zika
20 IV Inactivated virus Inactivated SARS-CoV2
21 IV Inactivated virus SARS-CoV2
22 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
23 IV Inactivated virus Inactivated + CpG 1018 SARS-CoV2
24 IV Inactivated virus Inactivated whole virus SARS-CoV2
25 IV Inactivated virus Inactivated SARS-CoV2
26 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
27 IV Inactivated virus Inactivated SARS-CoV2 MMR, IPV
28 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2

29 LAV Live attenuated virus Codon deoptimized live attenuated vaccines SARS-CoV2
30 LABV Live attenuated bacterial vector Live attenuated bacterial (Pertussis) Vector SARS-CoV2
31 LABV Live attenuated bacterial vector Live attenuated bacterial vector SARS-CoV2
32 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2
33 VVnr Viral vector (Non-replicating) Sendai virus vector SARS-CoV2 RSV, CMV
34 VVnr Viral vector (Non-replicating) Adenovirus-based SARS-CoV2
35 VVnr Viral vector (Non-replicating) Adeno-associated virus vector (AAVCOVID) SARS-CoV2
36 VVnr Viral vector (Non-replicating) MVA encoded VLP SARS-CoV2 LASV, EBOV, MARV, HIV
37 VVnr Viral vector (Non-replicating) MVA-S encoded SARS-CoV2 Multiple candidates
38 VVnr Viral vector (Non-replicating) MVA-S SARS-CoV2
39 VVnr Viral vector (Non-replicating) Adeno5-based SARS-CoV2
40 VVnr Viral vector (Non-replicating) Ad5 S (GREVAX™ platform) SARS-CoV2 MERS
41 VVnr Viral vector (Non-replicating) Oral Ad5 S SARS-CoV2 Zika, VZV, HSV-2 and Norovirus
42 VVnr Viral vector (Non-replicating) adenovirus-based + HLA-matched peptides Pan-Corona
43 VVnr Viral vector (Non-replicating) MVA expressing structural proteins SARS-CoV2 Multiple candidates
44 VVnr Viral vector (Non-replicating) Parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein SARS-CoV2 MERS
45 VVnr Viral vector (Non-replicating) Recombinant deactivated rabies virus containing S1 SARS-CoV2 HeV, NiV, EBOV, LASSA, CCHFV,
MERS
46 VVnr Viral vector (Non-replicating) Influenza A H1N1 vector SARS-CoV2
47 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing the spike protein SARS-CoV2
48 VVnr Viral vector (Non-replicating) Newcastle disease virus expressing membrane-anchored spike SARS-CoV2
49 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
50 VVnr Viral vector (Non-replicating) Lentiviral Vector SARS-CoV2
51 VVnr Viral vector (Non-replicating) Lentiviral Vector Retro-VLP Particles SARS-CoV2
52 VVnr Viral vector (Non-replicating) Ad 5 vector for intranasal administration SARS-CoV2
VVnr Viral vector (Non-replicating) Oral vaccine platform SARS-CoV2 InfA, CHIKV, LASV, NORV; EBOV,
53 RVF, HBV, VEE
54 PS Protein subunit RBD protein delivered in mannose-conjugated chitosan nanoparticle SARS-CoV2
55 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2
56 PS Protein subunit Peptides SARS-CoV2
57 PS Protein subunit Recombinant spike protein with Essai O/W 1849101 adjuvant SARS-CoV2
58 PS Protein subunit Recombinant S protein SARS-CoV2
59 PS Protein subunit RBD protein (baculovirus production) + FAR-Squalene adjuvant SARS-CoV2 Multiple candidates
60 PS Protein subunit Protein Subunit SARS-CoV2
61 PS Protein subunit RBD-protein SARS-CoV2
62 PS Protein subunit Recombinant S protein SARS-CoV2
63 PS Protein subunit Peptide + novel adjuvant SARS-CoV2
64 PS Protein subunit S subunit intranasal liposomal formulation with GLA/3M052 adjs. SARS-CoV2
65 PS Protein subunit S-Protein (Subunit) + Adjuvant, E coli based Expression SARS-CoV2
66 PS Protein subunit Protein Subunit S,N,M&S1 protein SARS-CoV2
67 PS Protein subunit Protein Subunit SARS-CoV2
68 PS Protein subunit RBD protein fused with Fc of IgG + Adj. SARS-CoV2
69 PS Protein subunit Capsid-like Particle SARS-CoV2
70 PS Protein subunit Drosophila S2 insect cell expression system VLPs SARS-CoV2
71 PS Protein subunit Peptide antigens formulated in LNP SARS-CoV2
72 PS Protein subunit S protein SARS-CoV2
73 PS Protein subunit S protein +Adjuvant SARS-CoV2 Influenza
74 PS Protein subunit VLP-recombinant protein + Adjuvant SARS-CoV2
75 PS Protein subunit microneedle arrays S1 subunit SARS-CoV2 MERS
76 PS Protein subunit Peptide SARS-CoV2
77 PS Protein subunit Adjuvanted protein subunit (RBD) SARS-CoV2
Ebola, Marburg, HIV, Zika,
78 PS Protein subunit Peptide SARS-CoV2 Influenza, HPV therapeutic
vaccine, BreastCA vaccine
79 PS Protein subunit S protein SARS-CoV2
80 PS Protein subunit Ii-Key peptide SARS-CoV2 Influenza, HIV, SARS-CoV
81 PS Protein subunit S protein SARS-CoV2 H7N9
82 PS Protein subunit Protein Subunit EPV-CoV-19 SARS-CoV2
83 PS Protein subunit gp-96 backbone SARS-CoV2 NSCLC, HIV, Malaria, Zika
84 PS Protein subunit Subunit vaccine SARS-CoV2
85 PS Protein subunit S1 or RBD protein SARS-CoV2 SARS
86 PS Protein subunit Subunit protein, plant produced SARS-CoV2
PS Protein subunit Recombinant protein, nanoparticles (based on S-protein and other epitopes) SARS-CoV2
87

Cross-reactive T-cell recombinant vaccine based on SARS-CoV-2 nucleoprotein

88 PS Protein subunit (N) expressed in E.coli SARS-CoV2 various (cross-immunity)

89 PS Protein subunit COVID-19 XWG-03 truncated S (spike) proteins SARS-CoV2 HPV

90 PS Protein subunit Adjuvanted microsphere peptide SARS-CoV2
91 PS Protein subunit Synthetic Long Peptide Vaccine candidate for S and M proteins SARS-CoV2
92 PS Protein subunit Oral E. coli-based protein expression system of S and N proteins SARS-CoV2
93 PS Protein subunit Nanoparticle vaccine SARS-CoV2
94 PS Protein subunit Plant-based subunit (RBD-Fc + Adjuvant) SARS-CoV2
95 PS Protein subunit OMV-based vaccine SARS-CoV2 Flu A, Plague
96 PS Protein subunit OMV-based vaccine SARS-CoV2
97 PS Protein subunit structurally modified spherical particles of the tobacco mosaic virus (TMV) SARS-CoV2 Rubella, Rotavirus
98 PS Protein subunit Spike-based SARS-CoV2 Hepatitis C
99 PS Protein subunit Recombinant S1-Fc fusion protein SARS-CoV2
100 PS Protein subunit Recombinant protein SARS-CoV2
101 PS Protein subunit Recombinant S protein in IC-BEVS (Viral vector vaccine SARS-CoV2
(based on baculovirus expression system in insect cell line)
102 PS Protein subunit Orally delivered, heat stable subunit SARS-CoV2
103 PS Protein subunit Peptides derived from Spike protein SARS-CoV2
104 PS Protein subunit Protein Subunit SARS-CoV2
105 PS Protein subunit RBD-based SARS-CoV2
106 PS Protein subunit Outer Membrane Vesicle (OMV)-subunit SARS-CoV2
107 PS Protein subunit Spike-based (epitope screening) SARS-CoV2
108 PS Protein subunit Spiked-based SARS-CoV2
109 PS Protein subunit Recombinant spike with adjuvant SARS-CoV2
110 PS Protein subunit Recombinant S protein produced in BEVS SARS-CoV2
111 PS Protein subunit Protein Subunit Nanoformulated SARS-CoV2
112 PS Protein subunit Protein Subunit Adenoviral Carrier SARS-CoV2
113 PS Protein subunit Protein DC-targeted epitopes SARS-CoV2
114 PS Protein subunit Soluble recombinant S protein produced in CHO cells SARS-CoV2
NYVAC-KC, attenuated vaccinia virus vector expressing SARS-CoV-2 Spike and
115 PS Protein subunit other viral proteins SARS-CoV2
116 PS Protein subunit Protein peptides with alum SARS-CoV2
117 PS Protein subunit Recombinant Spike (S) proteins encoded by Baculoviruses in Insect cells SARS-CoV2
118 PS Protein subunit Adjuvanted Peptides + Recombinant Spike Protein SARS-CoV2
119 PS Protein subunit Development of recombinant protein based S1 and S2 (Spike) and nucleocapsid SARS-CoV2
subunits vaccines using a plant expression vector.
120 PS Protein subunit Recombinant Protein Vaccine SARS-CoV2
121 PS Protein subunit Recombinant protein subunit vaccine SARS-CoV2
122 BVr Bacterial vector (Replicating) Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD SARS-CoV2 Multiple candidates
123 VVr Viral vector (Replicating) YF17D Vector SARS-CoV2
124 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
125 VVr Viral vector (Replicating) Measles Vector SARS-CoV2
126 VVr Viral vector (Replicating) Measles Virus (S, N targets) SARS-CoV2 Zika, H7N9, CHIKV
127 VVr Viral vector (Replicating) Horsepox vector expressing S protein SARS-CoV2 Smallpox, Monkeypox
128 VVr Viral vector (Replicating) Live viral vectored vaccine based on attenuated influenza virus backbone SARS-CoV2 Influenza
(intranasal)

129 VVr Viral vector (Replicating) Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 SARS-CoV2 Influenza
(intranasal)
130 VVr Viral vector (Replicating) Attenuated Influenza expressing an antigenic portion of the Spike protein SARS-CoV2 Influenza
131 VVr Viral vector (Replicating) Influenza vector expressing RBD SARS-CoV2
132 VVr Viral vector (Replicating) Replication-competent VSV chimeric virus technology (VSVΔG) delivering the SARS-CoV2 Ebola, Marburg, Lassa
SARS-CoV-2 Spike (S) glycoprotein.
133 VVr Viral vector (Replicating) Replicating VSV vector-based DC-targeting SARS-CoV2
134 VVr Viral vector (Replicating) VSV-S SARS-CoV2 HIV, MERS
135 VVr Viral vector (Replicating) VSV-S SARS-CoV2
136 VVr Viral vector (Replicating) VSV vector SARS-CoV2
137 VVr Viral vector (Replicating) M2-deficient single replication (M2SR) influenza vector SARS-CoV2 Influenza
138 VVr Viral vector (Replicating) Newcastle disease virus vector (NDV-SARS-CoV-2/Spike) SARS-CoV2
139 VVr Viral vector (Replicating) Avian paramyxovirus vector (APMV) SARS-CoV2
140 VVr Viral vector (Replicating) Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing RBD SARS-CoV2 Multiple candidates
protein: rNDV-LS1-HN-RBD/SARS-CoV-2

141 Intranasal Newcastle disease virus vector (rNDV-LS1-FARVET) expressing S1 SARS-CoV2 Multiple candidates
VVr Viral vector (Replicating) protein: rNDV-LS1-S1-F/SARS-CoV-2
142 RNA RNA based vaccine saRNA formulated in a NLC SARS-CoV2
143 RNA RNA based vaccine LNP-encapsulated mRNA encoding S SARS-CoV2
144 RNA RNA based vaccine Self-amplifying RNA SARS-CoV2
145 RNA RNA based vaccine mRNA SARS-CoV2
146 RNA RNA based vaccine LNP-mRNA SARS-CoV2
147 RNA RNA based vaccine LNP-mRNA SARS-CoV2
148 RNA RNA based vaccine LNP-encapsulated mRNA cocktail encoding VLP SARS-CoV2
149 RNA RNA based vaccine LNP-encapsulated mRNA encoding RBD SARS-CoV2
150 RNA RNA based vaccine Replicating Defective SARS-CoV-2 derived RNAs SARS-CoV2
151 RNA RNA based vaccine LNP-encapsulated mRNA SARS-CoV2 MERS
152 RNA RNA based vaccine Liposome-encapsulated mRNA SARS-CoV2
153 RNA RNA based vaccine Several mRNA candidates SARS-CoV2
154 RNA RNA based vaccine mRNA SARS-CoV2
155 RNA RNA based vaccine mRNA SARS-CoV2
156 RNA RNA based vaccine mRNA in an intranasal delivery system SARS-CoV2
157 RNA RNA based vaccine mRNA SARS-CoV2
158 RNA RNA based vaccine mRNA SARS-CoV2
159 RNA RNA based vaccine mRNA SARS-CoV2
160 RNA RNA based vaccine mRNA SARS-CoV2
161 RNA RNA based vaccine mRNA SARS-CoV2
162 RNA RNA based vaccine D614G variant LNP-encapsulated mRNA SARS-CoV2
163 RNA RNA based vaccine Encapsulated mRNA SARS-CoV2
164 RNA RNA based vaccine Recombinant, prefusion stabilized SARS-CoV-2 Spike antigen SARS-CoV2
165 RNA RNA based vaccine ZIP1642 is a self-amplifying RNA vaccine encapsulated in an LNP, which encodes SARS-CoV2
for multiple antigens, including the Spike (S) protein.

166 PS Protein subunit Multiple peptides fragments targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins SARS-CoV2
to induce T cell responses (CD8)
167 VLP Virus like particle VLP SARS-CoV2
168 VLP Virus like particle Virus-like particle-based Dendritic Cell(DC)-targeting vaccine SARS-CoV2
169 VLP Virus like particle VLP SARS-CoV2
170 VLP Virus like particle Enveloped Virus-Like Particle (eVLP) SARS-CoV-2, SARS-CoV, & CMV, GBM, Zika
MERS-CoV

171 VLP Virus like particle S protein integrated in HIV VLPs SARS-CoV2

172 VLP Virus like particle VLP + Adjuvant SARS-CoV2

173 VLP Virus like particle Virus-like particles, lentivirus and baculovirus vehicles SARS-CoV2
174 VLP Virus like particle Virus-like particle, based on RBD displayed on virus-like particles SARS-CoV2
175 VLP Virus like particle ADDomerTM multiepitope display SARS-CoV2
176 VLP Virus like particle Unknown SARS-CoV2
177 VLP Virus like particle VLP SARS-CoV1, SARS-CoV2
178 VLP Virus like particle eVLP SARS-CoV2 Malaria
179 VLP Virus like particle VLPs peptides/whole virus SARS-CoV2
180 VLP Virus like particle VLPs produced in BEVS SARS-CoV2
181 VLP Virus like particle Plant derived VLP SARS-CoV2
182 VLP Virus like particle Myxoma virus co-expressing S, M, N and E proteins SARS-CoV2
183 VLP Virus like particle Plasmid driven production of virus -Like-Particles (VLPs) containing S, M, N and E SARS-CoV2
proteins of SARS-CoV-2

184 Cell Cellular based vaccine Engineered human mesenchymal stem cells transfected with a plasmid SARS-CoV2
expressing S and N-protein
 Tuesday, March 30, 2021
sion of any particular product or entity in any of these landscape documents
verify the accuracy of the information presented in these landscape
d purposes), quality, safety, efficacy, merchantability and/or non-
ath, disability, injury, suffering, loss, damage or other prejudice of any kind

Developers

DIOSynVax Ltd + University of Cambridge

Ege University
Scancell/University of Nottingham/ Nottingham Trent University
Karolinska Institute / Cobra Biologics (OPENCORONA Project)
Chula Vaccine Research Center
Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet
National Research Centre, Egypt
BioNet Asia
Mediphage Bioceuticals/University of Waterloo
Entos Pharmaceuticals
Biosun Pharmed
Globe Biotech Limited, Bangladesh
National institute of Chemistry, Slovenia
Vaccibody, Oslo Research Park, Norway
Inserm

Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax /

PATH

Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH

Institute Butantan (Brazil) / Dynavax / PATH

KM Biologics
Selcuk University
Osaka University/ BIKEN/ NIBIOHN
Sinovac/Dynavax
Valneva/Dynavax
National Research Centre, Egypt
Kocak Farma Ilac ve Kimya San. A.S.
Milad Pharmaceutics Co.
Zista Kian Azma Co.
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S.

Indian Immunologicals Ltd/Griffith University

Institut Pasteur Lille, Inserm
ALtraBio, TheRex
ID Pharma
Max Planck Institute for Biochemstry/vir4vac, Germany
Ankara University
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis
GeoVax/BravoVax
DZIF – German Center for Infection Research/IDT Biologika GmbH
IDIBAPS-Hospital Clinic, Spain
Erciyes University
Greffex
Stabilitech Biopharma Ltd
Valo Therapeutics Ltd
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Georgia/University of Iowa
Bharat Biotech/Thomas Jefferson University

National Research Centre, Egypt

Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Theravectys – Institut Pasteur
AIOVA
Sorbonne University
University of Helsinki & University of Eastern Finland
Vaxart

Ohio State University / Kazakh National Agrarian University

Kazakh National Agrarian University
Neo7Logic
Kazakh National Agrarian University, Kazakhstan / National Scientific Center
for Especially Dangerous Infections
Max-Planck-Institute of Colloids and Interfaces
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana
Cayetano Heredia (UPCH)
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Mynvax
Izmir Biomedicine and Genome Center
Bogazici University
University of Virginia
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory,
Ogbomoso, Oyo State, Nigeria.
National Research Centre, Egypt
University of San Martin and CONICET, Argentina
Chulalongkorn University/GPO, Thailand
AdaptVac (PREVENT-nCoV consortium)
ExpreS2ion
IMV Inc
WRAIR/USAMRIID
National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan
Univ. of Pittsburgh
Vaxil Bio
Biological E Ltd

Flow Pharma Inc

AJ Vaccines
Generex/EpiVax
EpiVax/Univ. of Georgia
EpiVax
Heat Biologics/Univ. Of Miami
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Baylor College of Medicine
iBio/CC-Pharming
Saint-Petersburg scientific research institute of vaccines and serums

FSUE SPbSRIVS FMBA of Russia (St. Petersburg Institute of Vaccines)

Innovax/Xiamen Univ./GSK
VIDO-InterVac, University of Saskatchewan
OncoGen
MIGAL Galilee Research Institute
LakePharma, Inc.
Baiya Phytopharm/ Chula Vaccine Research Center
Quadram Institute Biosciences
BiOMViS Srl/Univ. of Trento
Lomonosov Moscow State University
University of Alberta
AnyGo Technology
Yisheng Biopharma
Vabiotech, Vietnam and University of Bristol, UK
Applied Biotechnology Institute, Inc.
Axon Neuroscience SE
MOGAM Institute for Biomedical Research, GC Pharma
Neovii/Tel Aviv University
Intravacc/Epivax
ImmunoPrecise/LiteVax BV
Nanografi Nano Technology, Middle East Technical University, Ankara
University,
Iran
Tampere University
Vaxinano, CEA, INRAE
CEA, CNRS
LinkinVax, VRI, Inserm
Center for Advanced Technologies, Uzbekistan
Arizona State University

Hacettepe University, Turkey

Marmara University, Turkey
Yıldız Technical University, Turkey
Akdeniz University, Department of Agricultural Biotechnology, Antalya, Turkey
Ataturk University, Vaccine Research Center (Erzurum) and Health Institutes of
Turkey (TUSEB)
Pharmada Pharmaceuticals/TURKEY

Farmacológicos Veterinarios SAC (FARVET SAC)

KU Leuven
Cadila Healthcare Limited
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
DZIF – German Center for Infection Research/CanVirex AG
Tonix Pharma/Southern Research
BiOCAD and IEM

FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo

Fundação Oswaldo Cruz and Instituto Buntantan
University of Hong Kong
IAVI/Merck
University of Manitoba
University of Western Ontario
Aurobindo
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
UW–Madison/FluGen/Bharat Biotech
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
The Lancaster University, UK
Farmacológicos Veterinarios SAC (FARVET SAC)

Farmacológicos Veterinarios SAC (FARVET SAC)

Infectious Disease Research Institute/ Amyris, Inc.
Max-Planck-Institute of Colloids and Interfaces
Gennova
Selcuk University
Translate Bio/Sanofi Pasteur
CanSino Biologics/Precision NanoSystems
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma
Centro Nacional Biotecnología (CNB-CSIC), Spain
University of Tokyo/ Daiichi-Sankyo
BIOCAD
RNAimmune, Inc.
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
China CDC/Tongji University/Stermina
eTheRNA
Greenlight Biosciences
IDIBAPS-Hospital Clinic, Spain
Providence Therapeutics
Cell Tech Pharmed
ReNAP Co.
Globe Biotech Ltd
CEA
Medigen Vaccines Biologics Corp (MVC)/Vaxess Technologies (MIMIX)
Ziphius Vaccines and Ghent University

OSE immunotherapeutics
Max Planck Institute for Dynamics of Complex Technical Systems
University of Manitoba
Bezmialem Vakif University
VBI Vaccines Inc.

IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing

Centre/Grifols
Mahidol University/ The Government Pharmaceutical Organization
(GPO)/Siriraj Hospital
Navarrabiomed, Oncoimmunology group
Saiba GmbH
Imophoron Ltd and Bristol University’s Max Planck Centre
Doherty Institute
OSIVAX
ARTES Biotechnology
Univ. of Sao Paulo
Tampere University
Shiraz University
Arizona State University
Arizona State University

Cell Tech Pharmed